Raquel Bissacotti Steglich

Raquel Bissacotti Steglich

Auto-generated profile, based on publicly available information

Raquel Bissacotti Steglich

Department of Dermatology, Universidade Regional de Joinville, Joinville, SC, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
RSRaquel Bissacotti Steglich
Raquel Bissacotti Steglich
KCKarina Munhoz de Paula Alves Coelho
Karina Munhoz de Paula Alves Coelho
SCSilvana Cardoso
Silvana Cardoso
MGMaria Helena da Costa Naumann Gaertner
Maria Helena da Costa Naumann Gaertner
TCTania Ferreira Cestari
Tania Ferreira Cestari
SFSelma Cristina Franco
Selma Cristina Franco
The worldwide incidence of cutaneous melanoma (CM) has been continuously increasing over the last decades. Primary and secondary prevention, with attention to risk factors and early diagnosis, remain the cornerstone for reducing the burden of cutaneous melanoma. Detailed information with respect to clinical and pathological data on cutaneous melanoma is scarce in Brazil. The purpose of our study was to analyze epidemiological and pathological characteristics of primary cutaneous melanoma in Joinville, southern Brazil. Observational, cross-sectional, retrospective study in which 893 reports of primary cutaneous melanoma from the local population were analyzed in the period 2003-2014. The study was approved by the local Ethics and Research Committee. We observed a female predominance of cutaneous melanoma (56.3%). The age standardized incidence rate of primary cutaneous melanoma for the world population in the period 2003-06 was 11.8 per 100,000 population (CI 95%, 10.3-13.4), and 17.5 (CI 95%, 15.7-19.3) in 2011-14, revealing a significant increase of 48.3% (p < 0,05). Six and a half percent of patients had multiple cutaneous melanomas (mean 2.2 years and a maximum of 10.0 years between diagnoses). We observed significant differences between the location head/neck and cutaneous melanoma in situ, lower limb with Breslow depth S III and upper limb with Breslow depth S I. The comparison of the characteristics of cutaneous melanoma in the elderly and non-elderly (< 60 years old) showed significant differences with respect to all the variables studied. Using secondary data source. Joinville has high incidence coefficients for Brazilian standards, showing an increase in the incidence of cutaneous melanoma.

1 July 2014 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
RSRaquel Bissacotti Steglich
Raquel Bissacotti Steglich
LMLuana Pizarro Meneghello
Luana Pizarro Meneghello
ACAndré Vicente Esteves de Carvalho
André Vicente Esteves de Carvalho
HCHugo Cheinquer
Hugo Cheinquer
FMFernanda Melo Muller
Fernanda Melo Muller
FRFlávia Pereira Reginatto
Flávia Pereira Reginatto
Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the world's population. Immunobiological medications are prescribed for certain patients with severe forms of psoriasis, however, these drugs increase the risk of reactivation of viral diseases such as hepatitis B. We report the case of a patient with severe psoriasis with positive serology for the Hepatitis B virus, who received ustekinumab (a human monoclonal antibody against interleukin 12 and 23). In this patient, the use of ustekinumab did not reactivate the Hepatitis B virus. Given the high prevalence of chronic viral infections in patients who are candidates for biologic therapy, as well as the potential for reactivate chronic viral illness, randomized controlled studies are needed to assess the risks and benefits of such therapy in these populations.

1 October 2012 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
RSRaquel Bissacotti Steglich
Raquel Bissacotti Steglich
RTRenata Elise Tonoli
Renata Elise Tonoli
GPGiselle Martins Pinto
Giselle Martins Pinto
FMFernanda Melo Müller
Fernanda Melo Müller
IGIsabelle Maffei Guarenti
Isabelle Maffei Guarenti
EDErnani Siegmann Duvelius
Ernani Siegmann Duvelius
A 33-year-old woman presented with a 3-year history of progressive alopecia of the scalp. Past treatment with hydroxicloroquine did not show improvement. Physical examination revealed multiple areas of alopecia with atrophic aspect of the scalp, and axillary and pubic hypotrichosis. Dermoscopy showed hyperkeratosis and accentuation of follicular ostia. Anatomopathological examination revealed decrease in the number of hair follicles, upper perifollicular infiltrate and areas with fibrosis. The Piccardi-Lassueur-Graham-Little syndrome is a rare disorder, characterized by the triad of multifocal scarring alopecia of the scalp, keratotic follicular eruption and hypotrichosis of axillary and pubic regions. Management is a challenge and many medications tried have controversial results. We report a case of this rare syndrome which improved with corticoids.

1 August 2012 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
ETEmanuela Plech Thomé
Emanuela Plech Thomé
RSRaquel Bissacotti Steglich
Raquel Bissacotti Steglich
CMCarolina Degen Meotti
Carolina Degen Meotti
JSJoel Schwartz
Joel Schwartz
ABAna Letícia Boff
Ana Letícia Boff
Papular elastorrhexis is a rare acquired disease, first described in 1987 by Bordas, which has been very rarely reported in the literature. It is characterized by small asymptomatic non-follicular papules, mainly distributed in the trunk. Histology of the lesions shows homogenization of collagen and fragmentation of elastic fibers in the dermis. The rarity of this disease is probably due to the subtlety and benign nature of clinical and histopathological alterations, which can be easily confused with other pathologies. The authors report the case of a patient with exuberant clinical manifestations typical of elastorrhexis papular.

1 December 2012 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
RSRaquel Bissacotti Steglich
Raquel Bissacotti Steglich
CMCarolina Degeon Meotti
Carolina Degeon Meotti
MFMariana Silveira Ferreira
Mariana Silveira Ferreira
LLLouise Lovatto
Louise Lovatto
ACAndré Vicente Esteves de Carvalho
André Vicente Esteves de Carvalho
CCCarlos Gustavo Carneiro de Castro
Carlos Gustavo Carneiro de Castro
The clinical identification of amelanotic malignant melanoma (AMM) and hypomelanotic malignant melanoma (HMM) becomes difficult due to the lack of pigmentation and to the diverse clinical presentations. Dermoscopy is very useful in these cases, increasing the level of suspicion of malignancy. We report 4 cases of amelanotic malignant melanoma and hypomelanotic malignant melanoma with characteristic dermoscopic findings. Dermoscopy under polarized light demonstrates vascular polymorphism, globules and milky-red areas, in addition to chrysalis and multiple blue-gray dots.

31 March 2025 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
JSJúlia Opolski Nunes da Silva
Júlia Opolski Nunes da Silva
RSRodrigo Ribeiro e Silva
Rodrigo Ribeiro e Silva
PRPaulo Victor Zattar Ribeiro
Paulo Victor Zattar Ribeiro
PFPatrícia Silva Farah
Patrícia Silva Farah
RSRaquel Bissacotti Steglich
Raquel Bissacotti Steglich
Evaluate the safety and efficacy of dupilumab in treating moderate-to-severe bullous pemphigoid. The authors performed a systematic review and meta-analysis of comparative studies of Dupilumab combined with corticosteroids and conventional corticosteroid therapy alone in patients with moderate-to-severe bullous pemphigoid. PubMed, Embase and Cochrane databases were searched for studies published up to December 2023. Data were extracted from published reports and quality assessment was performed according to Cochrane recommendations. A total of four studies involving 127 patients were included, of which 53 received Dupilumab combined with corticosteroids, while the other 74 were administered corticosteroids alone. Regarding efficacy, Dupilumab the time before new blister formation stopped (MD = -5.13 days; 95% CI -7.12 to -3.15; p < 0.0001) and demonstrated a greater reduction in Bullous Pemphigoid Disease Area Index (MD = -3.90; 95% CI -5.52 to -2.27; p < 0.0001) and Numeric Rating Scale for Pruritus (SMD = -1.37; 95% CI -2.02 to -0.72; p < 0.0001) compared with patients who received conventional therapy. However safety endpoints, adverse events (RR = 0.78; 95% CI 0.58 to 1.05; p = 0.10) and relapses (RR = 0.50; 95% CI 0.19 to 1.36; p = 0.17) showed no significance. The main limitations were retrospective studies with small samples and limited results in clinical practice and a moderate overall risk of bias. Compared with conventional therapy, Dupilumab decreased the time before new blister formation stopped in 5.13 days, as well as Disease Area Index and Pruritus, without interfering with adverse events and relapse.